Gain Therapeutics to Present at the 38th Annual ROTH Conference
Rhea-AI Summary
Gain Therapeutics (NASDAQ: GANX) announced that Gene Mack, President and CEO, will participate in a fireside chat and one-on-one meetings at the 38th Annual ROTH Conference in Dana Point, CA, March 22-24, 2026. The fireside chat is scheduled for March 23, 2026 at 11:30 a.m. PT.
Investors can access a live webcast or replay via the company website or contact ir@gaintherapeutics.com to arrange meetings through ROTH representatives.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Two biotech peers, CUE and INKT, appeared on the momentum scanner, both moving down about 5–6%. This aligns with broader weakness in the biotechnology group around this time.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Clinical data update | Positive | -25.6% | Phase 1b GT-02287 and new chemical series data presented at AD/PD 2026. |
| Mar 12 | Conference & FDA update | Positive | -3.2% | AD/PD 2026 presentation plans and U.S. FDA IND response timeline for Phase 2. |
| Feb 19 | Conference participation | Neutral | +3.3% | Oppenheimer conference fireside chat and one-on-one investor meetings. |
| Jan 07 | Conference participation | Neutral | -5.5% | Participation in multiple JPM Healthcare Conference–week investor events. |
| Jan 06 | Biomarker data update | Positive | -14.1% | Phase 1b GT-02287 biomarker and clinical results showing large GluSph reductions. |
Recent positive clinical and biomarker updates have often been followed by negative price reactions, indicating a pattern of selling into good news.
Over the past six months, GANX has focused on advancing GT-02287 and increasing visibility through conferences. Biomarker and clinical data releases on Jan 6, 2026 and Dec 18, 2025 highlighted substantial GluSph reductions and supportive safety data, yet shares fell 14.14% and showed pressure after these updates. The Mar 18, 2026 AD/PD Phase 1b data coincided with a 25.57% drop. Multiple conference participation announcements (January, February) produced mixed but generally modest moves. Today’s ROTH conference news fits the pattern of ongoing outreach rather than a new clinical or financial catalyst.
Regulatory & Risk Context
An amended mixed shelf registration on Nov 7, 2025 registered up to $100,000,000 of various securities for potential future offerings. The filing is noted as not yet effective and has not been used to date, but it provides flexibility to raise capital for working capital and general corporate purposes if activated.
Market Pulse Summary
This announcement highlights GANX’s participation in the 38th Annual ROTH Conference, continuing a strategy of active investor outreach via events and fireside chats. It follows recent Phase 1b data for GT-02287 and ongoing regulatory updates. From a fundamental standpoint, investors may focus on liquidity metrics such as cash of $8.81M at Sept 30, 2025, prior net losses of $5.28M in Q3 2025, and the existing $100,000,000 mixed shelf that could support future capital raising.
Key Terms
allosteric medical
small molecule medical
AI-generated analysis. Not financial advice.
BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in a fireside chat and one-on-one meetings at the 38th Annual ROTH Conference, being held March 22-24, 2026, in Dana Point, CA.
Fireside Chat Details
Date: Monday, March 23, 2026
Time: 11:30 a.m. PT
Access a live webcast or a replay of the fireside chat here or visit the “Investors & Media/News & Events” section of the Company’s website at https://gaintherapeutics.com.
If you are unable to attend the conference and would like to schedule a meeting with Gain management, please contact either your ROTH representative or ir@gaintherapeutics.com.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding: the development of the Company’s current or future product candidates including GT-02287 and GT-04686; expectations regarding the completion and timing of results from a Phase 1b clinical study for GT-02287, including any extension studies; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287, including any extension studies; the timing of any submissions to the FDA or other regulatory bodies and agencies and the timing of any responses from the FDA or other regulatory bodies and agencies; the timing of the commencement of any Phase 2 clinical studies for GT-02287; and the potential therapeutic and clinical benefits of the Company’s product candidates, including GT-02287 and GT-04686. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2024, and other filings made with the SEC. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information, future events or otherwise.
Investors:
Gain Therapeutics, Inc.
Apaar Jammu
Director, Investor Relations and Public Relations
ajammu@gaintherapeutics.com
LifeSci Advisors LLC
Chuck Padala
Managing Director
chuck@lifesciadvisors.com
Media:
Russo Partners LLC
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
FAQ
When will Gain Therapeutics (GANX) present at the 38th Annual ROTH Conference?
How can investors watch Gain Therapeutics (GANX) at the ROTH Conference if they cannot attend?
Who from Gain Therapeutics (GANX) will participate at the ROTH Conference?
How can I schedule a meeting with Gain Therapeutics (GANX) management at ROTH Conference?
Where is the 38th Annual ROTH Conference held for Gain Therapeutics (GANX)?
Will Gain Therapeutics (GANX) provide a replay of the ROTH Conference fireside chat?
